Literature DB >> 3604970

Gaseous response to ingestion of a poorly absorbed fructo-oligosaccharide sweetener.

T Stone-Dorshow, M D Levitt.   

Abstract

Fructo-oligosaccharides are naturally occurring sweet substances that are poorly absorbed and have the potential to be clinically useful nonnutritive sweeteners. Because most nonabsorbed carbohydrates are fermented yielding gas, we assessed flatulent symptoms and H2 excretion during ingestion of fructo-oligosaccharide (5 g tid) for 12 d. Ten subjects had significantly greater flatulence while taking the oligosaccharide than did five subjects taking sucrose (5 g tid). Breath H2 after 10 g fructo-oligosaccharide was similar to that of 10 g lactulose, suggesting near total malabsorption of the fructo-oligosaccharide. Although previous studies found a marked diminution in breath H2 after prolonged exposure to lactulose, breath H2 response increased by 50% after a 12-d period on the oligosaccharide and gaseous symptoms did not improve. We conclude that adaptation of colonic bacteria to carbohydrate malabsorption is variable and may depend upon quantity or nature of the carbohydrate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3604970     DOI: 10.1093/ajcn/46.1.61

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  19 in total

Review 1.  Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health?

Authors:  G T Macfarlane; J H Cummings
Journal:  BMJ       Date:  1999-04-10

2.  Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel.

Authors:  S J Langlands; M J Hopkins; N Coleman; J H Cummings
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

3.  Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health?

Authors:  G T Macfarlane; J H Cummings
Journal:  West J Med       Date:  1999-09

4.  Prevalence and consistency of low breath H2 excretion following lactulose ingestion. Possible implications for the clinical use of the H2 breath test.

Authors:  G Corazza; A Strocchi; M Sorge; G Bentai; G Gasbarrini
Journal:  Dig Dis Sci       Date:  1993-11       Impact factor: 3.199

5.  Effects of Fructo-Oligosaccharide Supplementation on Constipation in Elderly Continuous Ambulatory Peritoneal Dialysis Patients.

Authors:  Kulwara Meksawan; Chorsakon Chaotrakul; Napat Leeaphorn; Suthep Gonlchanvit; Somchai Eiam-Ong; Talerngsak Kanjanabuch
Journal:  Perit Dial Int       Date:  2014-10-07       Impact factor: 1.756

6.  Fructose malabsorption may be gender dependent and fails to show compensation by colonic adaptation.

Authors:  Andrew Szilagyi; Paula Malolepszy; Samara Yesovitch; Christina Vinokuroff; Usha Nathwani; Albert Cohen; Xiaoqing Xue
Journal:  Dig Dis Sci       Date:  2007-03-15       Impact factor: 3.199

7.  Comparison of diarrhea induced by ingestion of fructooligosaccharide Idolax and disaccharide lactulose: role of osmolarity versus fermentation of malabsorbed carbohydrate.

Authors:  M R Clausen; J Jørgensen; P B Mortensen
Journal:  Dig Dis Sci       Date:  1998-12       Impact factor: 3.199

8.  Diminished efficacy of colonic adaptation to lactulose occurs in patients with inflammatory bowel disease in remission.

Authors:  Andrew Szilagyi; Julie Rivard; Ian Shrier
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

9.  Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.

Authors:  Mariano Malaguarnera; Filippo Greco; Gloria Barone; Maria Pia Gargante; Michele Malaguarnera; Maria Antonietta Toscano
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

10.  High purity galacto-oligosaccharides enhance specific Bifidobacterium species and their metabolic activity in the mouse gut microbiome.

Authors:  A Monteagudo-Mera; J C Arthur; C Jobin; T Keku; J M Bruno-Barcena; M A Azcarate-Peril
Journal:  Benef Microbes       Date:  2016-02-03       Impact factor: 4.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.